➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
McKesson
Merck
Mallinckrodt
Express Scripts

Last Updated: June 12, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for HIP1402


Email this page to a colleague

« Back to Dashboard

What is the drug development status for HIP1402?

HIP1402 is an investigational drug.

There have been 5 clinical trials for HIP1402. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2014.

The most common disease conditions in clinical trials are Prostatic Hyperplasia, Hyperplasia, and Erectile Dysfunction. The leading clinical trial sponsors are Hanmi Pharmaceutical Company Limited and [disabled in preview].

There is one US patent protecting this investigational drug and fourteen international patents.

Recent Clinical Trials for HIP1402
TitleSponsorPhase
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1801 in Healthy Male Subjects.Hanmi Pharmaceutical Company LimitedPhase 1
PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male VolunteersHanmi Pharmaceutical Company LimitedPhase 1
Investigating the Pharmacokinetic Characteristics of HIP1402 in Healthy Male VolunteersHanmi Pharmaceutical Company LimitedPhase 1

See all HIP1402 clinical trials

Clinical Trial Summary for HIP1402

Top disease conditions for HIP1402
Top clinical trial sponsors for HIP1402

See all HIP1402 clinical trials

US Patents for HIP1402

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
HIP1402   Get Started Free Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof The Regents of the University of California (Oakland, CA)   Get Started Free
HIP1402   Get Started Free Therapeutic compounds and methods of use thereof GENENTECH, INC. (South San Francisco, CA) XENON PHARMACEUTICALS INC. (Burnaby, BC, CA)   Get Started Free
HIP1402   Get Started Free Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Get Started Free
HIP1402   Get Started Free Matrix and layer compositions for protection of bioactives Novus International, Inc. (St. Charles, MO)   Get Started Free
HIP1402   Get Started Free Ultra-pure agonists of guanylate cyclase C, method of making and using same SYNERGY PHARMACEUTICALS, INC. (New York, NY)   Get Started Free
HIP1402   Get Started Free Secure handle for intra-and inter-processor communications III HOLDINGS 1, LLC (Wilmington, DE)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for HIP1402

Drugname Country Document Number Estimated Expiration Related US Patent
HIP1402 European Patent Office EP2981556 2033-04-02   Get Started Free
HIP1402 World Intellectual Property Organization (WIPO) WO2014165513 2033-04-02   Get Started Free
HIP1402 China CN106715418 2034-07-07   Get Started Free
HIP1402 European Patent Office EP3166939 2034-07-07   Get Started Free
HIP1402 Japan JP2017525677 2034-07-07   Get Started Free
HIP1402 World Intellectual Property Organization (WIPO) WO2016007534 2034-07-07   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Merck
Dow
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.